Evidence map›Paper›PMID 24735329›Full record

ArticleEndocrinology2014

ESR1 and ESR2 differentially regulate daily and circadian activity rhythms in female mice.

S E Royston, N Yasui, A G Kondilis, S V Lord, J A Katzenellenbogen, M M Mahoney

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Hypertension disrupts the vascular clock in both sexes.American journal of physiology. Heart and circulatory physiology · 2024
    Article
  4. Review
  5. Sex difference in cardiac performance in individuals with irregular shift work.International journal of cardiology. Cardiovascular risk and prevention · 2023
    Article
  6. Review
  7. Article
  8. Circadian Responses to Light in the BTBR Mouse.Journal of biological rhythms · 2022
    Article
  9. Sex differences in daily timekeeping and circadian clock circuits.Seminars in cell & developmental biology · 2022
    Review
  10. Estrogens and the circadian system.Seminars in cell & developmental biology · 2022
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Estrogens in Male Physiology.Physiological reviews · 2017
    Review
  16. Article
  17. Neuroendocrine underpinnings of sex differences in circadian timing systems.The Journal of steroid biochemistry and molecular biology · 2016
    Review
  18. Article
  19. Melatonin: an inhibitor of breast cancer.Endocrine-related cancer · 2015
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

S E RoystonNeuroscience Program (S.E.R., M.M.M.), Medical Scholars Program (S.E.R.), and Departments of Chemistry (N.Y., J.A.K.) and Comparative Biosciences (A.G.K., S.V.L., M.M.M.), University of Illinois Urbana-Champaign, Urbana, Illinois 61802.
N Yasui
A G Kondilis
S V Lord
J A Katzenellenbogen
M M Mahoney
University of Illinois Urbana-Champaign · US

Funding

Novel Ligands and Mechanisms to Achieve Selective Nuclear Receptor ActivityR01DK015556 · NIDDK · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI KATZENELLENBOGEN, JOHN A. · 1986 to 2016
$1.6M
NIDDK NIH HHS 5R01DK015556NIDDK NIH HHS R01 DK015556
6 · The paper itself

Abstract

Estrogenic signaling shapes and modifies daily and circadian rhythms, the disruption of which has been implicated in psychiatric, neurologic, cardiovascular, and metabolic disease, among others. However, the activational mechanisms contributing to these effects remain poorly characterized. To determine the activational impact of estrogen on daily behavior patterns and differentiate between the contributions of the estrogen receptors ESR1 and ESR2, ovariectomized adult female mice were administered estradiol, the ESR1 agonist propylpyrazole triol, the ESR2 agonist diarylpropionitrile, or cholesterol (control). Animals were singly housed with running wheels in a 12-hour light, 12-hour dark cycle or total darkness. Estradiol increased total activity and amplitude, consolidated activity to the dark phase, delayed the time of peak activity (acrophase of wheel running), advanced the time of activity onset, and shortened the free running period (τ), but did not alter the duration of activity (α). Importantly, activation of ESR1 or ESR2 differentially impacted daily and circadian rhythms. ESR1 stimulation increased total wheel running and amplitude and reduced the proportion of activity in the light vs the dark. Conversely, ESR2 activation modified the distribution of activity across the day, delayed acrophase of wheel running, and advanced the time of activity onset. Interestingly, τ was shortened by estradiol or either estrogen receptor agonist. Finally, estradiol-treated animals administered a light pulse in the early subjective night, but no other time, had an attenuated response compared with controls. This decreased phase response was mirrored by animals treated with diarylpropionitrile, but not propylpyrazole triol. To conclude, estradiol has strong activational effects on the temporal patterning and expression of daily and circadian behavior, and these effects are due to distinct mechanisms elicited by ESR1 and ESR2 activation.

Indexed as

Analysis of VarianceAnimalsCircadian RhythmEstradiolEstrogen Receptor alphaEstrogen Receptor betaEstrogensFemaleMiceMice, Inbred C57BLMice, KnockoutMotor ActivityNitrilesOvariectomyPhenolsPhotoperiod2,3-bis(4-hydroxyphenyl)-propionitrile4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenolEstradiolEstrogen Receptor alphaEstrogen Receptor betaEstrogensNitrilesPhenolsPropionatesPyrazoles

Identifiers

PMID24735329
PMCPMC5393318
OpenAlexW2027774077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.